| 0 (0%) | 06-09 17:21 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.07  |
1-year : | 30.92 |
| Resists | First : | 24.03 |
Second : | 26.47 |
| Pivot price | 23.63 |
|||
| Supports | First : | 20.09 | Second : | 16.71 |
| MAs | MA(5) : | 21.5 |
MA(20) : | 23.75 |
| MA(100) : | 25.59 |
MA(250) : | 16.51 |
|
| MACD | MACD : | -1 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 13.6 |
D(3) : | 17.3 |
| RSI | RSI(14): 31.1 |
|||
| 52-week | High : | 38.32 | Low : | 2.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DMRA ] has closed above bottom band by 10.1%. Bollinger Bands are 8.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.27 - 22.42 | 22.42 - 22.55 |
| Low: | 19.76 - 19.94 | 19.94 - 20.09 |
| Close: | 20.68 - 20.97 | 20.97 - 21.22 |
Mon, 08 Jun 2026
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Mon, 08 Jun 2026
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Mon, 08 Jun 2026
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Mon, 01 Jun 2026
Six new Damora hires get 372,000 stock options in Nasdaq inducement grants - Stock Titan
Wed, 27 May 2026
Damora Therapeutics: Well-Funded Moonshot For CALR Mutations (NASDAQ:DMRA) - Seeking Alpha
Tue, 26 May 2026
Damora Therapeutics’ Deepening Losses Raise a Quiet Question About Its Cost Strategy and Runway (DMRA) - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 62 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 7.6 (%) |
| Held by Institutions | 91 (%) |
| Shares Short | 1,290 (K) |
| Shares Short P.Month | 1,120 (K) |
| EPS | -2.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.7 % |
| Return on Equity (ttm) | -89.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -7.83 |
| PEG Ratio | 0 |
| Price to Book value | 3.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -51.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|